Laboratory of physical chemistry of drug compounds

Main research themes of the Laboratory:

“Development of scientific basis for creation of neurodegenerative and anti-inflammation drug compounds and forms with improved solubility and permeability characteristics”

Head of the Laboratory: Perlovich G.L., PhD, DSc

The main problems:

In spite of the fact that in many cases affinity to the receptors is obviously a key moment for the potential drug compound candidates, other factors such as solubility, distribution in the immiscible phases, absorption properties, active and passive transport characteristics are also of a great importance for in vivo processes. Unfortunately the above aspects are taking into account only on the final stages of preparation’s screening and design. As a result, the selected candidates possessing the best affinities to the receptors reveal in vitro a wide spectrum of undesirable properties: low solubility in biologically relevant media and extremely poor membrane permeability. Just these points are the serious barriers for the potential candidates («hit-compounds») to become an effective drugs. Even the contemporary advancements of drug substances delivery by means of the complicated pharmaceutical systems can’t compensate the above mentioned limitations. A much more effective and economical way assumes controlling the permeability of the compounds through the different types of membranes on the stages preceding biological and preclinical testing. As a result, not only the facilities economy of highly expensed in-vivo tests occurs, but also the procedure of choosing the «leader-compound» is considerably promoted.

To solve the problems in the Laboratory it is carrying out investigations in the following areas:

  • Development of drug compounds with neuroprotective and cognitive-stimulating actions;
  • Development of scientific basis for obtaining well soluble drug substances/forms by using cocrystal technology;
  • Development and design of High Throughput Screening (HTS) algorithms of membrane permeability of drug compounds;
  • Impact of structural modification of drug molecules (without disturbing pharmacological site) on ADME characteristics;
  • Polymorphism of drug compounds;
  • Development of drug delivery systems;

The studies are conducting:

  • Investigation of sublimation processes of drug compounds;
  • X-ray diffraction analysis and theoretical description of crystal lattice energies of molecular crystals;
  • Studying solubility and solvation processes of drug substances in biological relevant mediums;
  • Studying distribution/partitioning processes of drug compounds in the model systems;
  • Design of membranes modeling to the various biological barriers;
  • Investigation and analysis of membrane permeability of drug substances;
  • Studying intermolecular interactions of drugs in biological mediums, crystals and pharmaceutical systems;
  • Development of screening algorithms for obtaining pharmaceutical cocrystals;

Международное сотрудничество:

  • Болгария, Юго-Западный Университет “Неофит Рилски”, Благоевград
  • Индия, Индийский Институт Химической Технологии (IICT), Hyderabad
  • Китай, Университет Сунь Ят-Сена (Гуаньджоу)
  • Китай, Таньцзиньский Технологический Унверситет
  • Китай, Пекинский Технологический Институт
  • Китай, Шанхайский Институт Медицинских Материалов, Китайской Академии Наук (Шанхай)
  • ЮАР, Кейптаунский Университет, Химический факультет, Центр Супрамолекулярной химии (Кеуптаун)
  • Китай, Университет Сунь Ят-Сена (Гуаньджоу)
  • Норвегия, Институт Фармацевтики Университета Тромсё
  • Италия, Институт химических наук Университета Болоньи
  • Германия, Биомедицинский исследовательский центр (Борстель)
  • Германия, Федеральный институт исследования и тестирования материалов (Берлин)
  • Финляндия, Институт фармацевтики Университета Хельсинки
  • Швеция, Pharmaceutical and Analytical R&D, AstraZeneca R&D, Mölndal
  • Шотландия, Институт фармацевтики Университета Глазго
  • Дания, Институт физики и химии Южного университета Дании, Оденсе

Российское сотрудничество:

  • Институт физиологически активных веществ РАН, Черноголовка
  • Институт проблем химической физики РАН, Черноголовка
  • Институт общей и неорганической химии РАН, Москва

 

Main classes of the compounds for treating of socially significant diseases – the objects of the laboratory investigations.

Compounds for treating of Alzheimer’s disease.

Alzheimer’s disease is a common form of dementia disorder, characterized by the progressive decline of memory and highly cerebral functions that in the final analysis leads to the complete degradation of intellectual and cognitive activity. According to the social significance Alzheimer’s disease takes the third place after cancerous and cardiovascular diseases.Due to the real tendency of constant increasing the percentage of elderly population the search of new approaches aimed on the regeneration and improvement of brain cognitive functions and memory in biological aging and under the different age depended neurodegenerative disorders have been intensified last years. The tendency of screening and creating the positive modulators of NMDA-subtype Glu receptors as the potential cognition enhancers have been intensively developed last time.

                             

 

                             

 

Нестероидные антиантрогенные соединения

 

Противотуберкулезные соединения